Sign inJoin waitlistJoin the waitlist

Abdulrahman Sinno

Chief, Gynecologic Oncology · Jackson Memorial Hospital

Credentials: · · · · · ·

History

Gynecologic Oncology Division · Jackson Memorial Hospital
Present
Sylvester Comprehensive Cancer Center · Jackson Memorial Hospital
Present
Sylvester Comprehensive Cancer Center · University of Miami/Jackson Health System
Present

Gynecologic Oncology
Johns Hopkins University School of Medicine
2015–2018
Obstetrics and Gynecology
Emory University
2011–2015
University of Illinois
2008–2009
American Univ of Beirut, Beirut, Lebanon
2004–2008

Research

A comparison of colorimetric versus fluorometric sentinel lymph node mapping during robotic surgery for endometrial cancer
Gynecologic Oncology · 2014 · First of 5 authors · 100 citations
Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications
American Journal of Obstetrics and Gynecology · 2017 · 93 citations
Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer
Gynecologic Oncology · 2015 · 91 citations

ET
Edward Tanner
16 papers · 6 as a fellow
Rebecca Stone
10 papers · 9 as a fellow
Kimberly Levinson
7 papers · 7 as a fellow
Matthew Schlumbrecht
6 papers
ST
Sarah Temkin
6 papers
Marilyn Huang
3 papers
Navya Nair
3 papers
SW
Stephanie Wethington
3 papers
Alexandra Mardock
2 papers · 2 as a resident
Angeles Secord
2 papers
Bhavana Pothuri
2 papers
Christine Holschneider
2 papers

Clinical trials

A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
Principal investigator · Active not recruiting · Phase 2
University of Miami
2023–2026
Signatera Assessment in Early-Stage Endometrial Cancer
Site PI · Not yet recruiting
Natera, Inc.
2026–2034
Fasting InTervention for Endometrial Cancer
Site PI · Recruiting
University of Miami
2026–2028
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031